DE LUCA, G., M. CERCEK, L. O. JENSEN, O. BUSHLJETIKJ, L. CALMAC, T. JOHNSON, M. G. BLANCAS, V. GANYUKOV, W. WOJAKOWSKI, C. VON BIRGELEN, A. IJSSELMUIDEN, B. TUCCILLO, F. VERSACI, J. T. BERG, M. LAINE, T. BERKOUT, G. CASELLA, Petr KALA, B. L. LEDESMA, V. BECERRA, R. PADALINO, A. SANTUCCI, X. CARRILLO, A. SCOCCIA, G. AMOROSO, A. L. T. KOVARNIK, P. DAVLOUROS, G. GABRIELLI, X. F. RIOS, N. BAKRACESKI, S. LEVESQUE, V. GUIDUCCI, M. KIDAWA, L. MARINUCCI, F. ZILIO, G. GALASSO, E. FABRIS, M. MENICHELLI, S. MANZO, G. CAIAZZO, J. MOREU, J. S. FOR, L. DONAZZAN, L. VIGNALI, R. TELES, P. AGOSTONI, F. B. OJEDA, H. LEHTOLA, S. CAMACHO-FREIERE, A. KRAAIJEVELD, Y. ANTTI, G. VISCONTI, I. L. MARTINEZ-LUENGAS, B. SCHELLER, D. ALEXOPULOS, R. MORENO, E. KEDHI, G. UCCELLO, B. FAURIE, A. G. BARRIOS, F. S. DI UCCIO, B. WILBERT, G. CORTESE, M. T. DIRKSEN, G. PARODI and M. VERDOIA. Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. BIOMEDICINE & PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, vol. 138, June 2021, p. 1-7. ISSN 0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2021.111469.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry
Authors DE LUCA, G. (guarantor), M. CERCEK, L. O. JENSEN, O. BUSHLJETIKJ, L. CALMAC, T. JOHNSON, M. G. BLANCAS, V. GANYUKOV, W. WOJAKOWSKI, C. VON BIRGELEN, A. IJSSELMUIDEN, B. TUCCILLO, F. VERSACI, J. T. BERG, M. LAINE, T. BERKOUT, G. CASELLA, Petr KALA (203 Czech Republic, belonging to the institution), B. L. LEDESMA, V. BECERRA, R. PADALINO, A. SANTUCCI, X. CARRILLO, A. SCOCCIA, G. AMOROSO, A. L. T. KOVARNIK, P. DAVLOUROS, G. GABRIELLI, X. F. RIOS, N. BAKRACESKI, S. LEVESQUE, V. GUIDUCCI, M. KIDAWA, L. MARINUCCI, F. ZILIO, G. GALASSO, E. FABRIS, M. MENICHELLI, S. MANZO, G. CAIAZZO, J. MOREU, J. S. FOR, L. DONAZZAN, L. VIGNALI, R. TELES, P. AGOSTONI, F. B. OJEDA, H. LEHTOLA, S. CAMACHO-FREIERE, A. KRAAIJEVELD, Y. ANTTI, G. VISCONTI, I. L. MARTINEZ-LUENGAS, B. SCHELLER, D. ALEXOPULOS, R. MORENO, E. KEDHI, G. UCCELLO, B. FAURIE, A. G. BARRIOS, F. S. DI UCCIO, B. WILBERT, G. CORTESE, M. T. DIRKSEN, G. PARODI and M. VERDOIA.
Edition BIOMEDICINE & PHARMACOTHERAPY, Paris, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, 0753-3322.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher France
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.419
RIV identification code RIV/00216224:14110/21:00123838
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.biopha.2021.111469
UT WoS 000641397100006
Keywords in English Renin-Angiotensin System inhibitors; ST-segment elevation myocardial infarction; Mortality; COVID-19; Percutaneous coronary intervention
Tags 14110211, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/1/2022 10:18.
Abstract
Background: Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study. Methods: STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission. Results: Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51-0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33-0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084-0.14], p < 0.0001), confirmed after adjustment in both periods. Among the 62 SARSCoV-2 positive patients, RASI therapy, both at admission or in-hospital, showed no prognostic effect. Conclusions: This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital RASI therapy showed no impact on survival.
PrintDisplayed: 21/8/2024 08:52